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In computational biology and other sciences, researchers are frequently faced with a choice between several computational
methods for performing data analyses. Benchmarking studies aim to rigorously compare the performance of different
methods using well-characterized benchmark datasets, to determine the strengths of each method or to
provide recommendations regarding suitable choices of methods for an analysis. However, benchmarking
studies must be carefully designed and implemented to provide accurate, unbiased, and informative results.
Here, we summarize key practical guidelines and recommendations for performing high-quality benchmarking
analyses, based on our experiences in computational biology.Introduction
Many fields of computational research are characterized
by a growing number of available methods for data ana-
lysis. For example, at the time of writing, almost 400
methods are available for analyzing data from single-cell
RNA-sequencing experiments [1]. For experimental re-
searchers and method users, this represents both an op-
portunity and a challenge, since method choice can
significantly affect conclusions.
Benchmarking studies are carried out by computa-
tional researchers to compare the performance of differ-
ent methods, using reference datasets and a range of
evaluation criteria. Benchmarks may be performed by
authors of new methods to demonstrate performance
improvements or other advantages; by independent
groups interested in systematically comparing existing
methods; or organized as community challenges. ‘Neu-
tral’ benchmarking studies, i.e., those performed inde-
pendently of new method development by authors
without any perceived bias, and with a focus on the
comparison itself, are especially valuable for the research
community [2, 3].© The Author(s). 2019 Open Access This artic
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Full list of author information is available at the end of the articleFrom our experience conducting benchmarking stud-
ies in computational biology, we have learned several
key lessons that we aim to synthesize in this review. A
number of previous reviews have addressed this topic
from a range of perspectives, including: overall commen-
taries and recommendations on benchmarking design [2,
4–9]; surveys of design practices followed by existing
benchmarks [7]; the importance of neutral benchmark-
ing studies [3]; principles for the design of real-data
benchmarking studies [10, 11] and simulation studies
[12]; the incorporation of meta-analysis techniques into
benchmarking [13–16]; the organization and role of
community challenges [17, 18]; and discussions on
benchmarking design for specific types of methods [19,
20]. More generally, benchmarking may be viewed as a
form of meta-research [21].
Our aim is to complement previous reviews by provid-
ing a summary of essential guidelines for designing, per-
forming, and interpreting benchmarks. While all
guidelines are essential for a truly excellent benchmark,
some are more fundamental than others. Our target
audience consists of computational researchers who are
interested in performing a benchmarking study, or who
have already begun one. Our review spans the full ‘pipe-
line’ of benchmarking, from defining the scope to best
practices for reproducibility. This includes crucial ques-
tions regarding design and evaluation principles: for ex-
ample, using rankings according to evaluation metrics tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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highlighting different strengths and tradeoffs among
these.
The review is structured as a series of guidelines
(Fig. 1), each explained in detail in the following sec-
tions. We use examples from computational biology;
however, we expect that most arguments apply equally
to other fields. We hope that these guidelines will con-
tinue the discussion on benchmarking design, as well as
assisting computational researchers to design and imple-
ment rigorous, informative, and unbiased benchmarking
analyses.
Defining the purpose and scope
The purpose and scope of a benchmark should be clearly
defined at the beginning of the study, and will fundamentally
guide the design and implementation. In general, we can de-
fine three broad types of benchmarking studies: (i) those by
method developers, to demonstrate the merits of their ap-
proach (e.g., [22–26]); (ii) neutral studies performed to sys-
tematically compare methods for a certain analysis, either
conducted directly by an independent group (e.g., [27–38])
or in collaboration with method authors (e.g., [39]); or (iii)
those organized in the form of a community challenge, such
as those from the DREAM [40–44], FlowCAP [45, 46],
CASP [47, 48], CAMI [49], Assemblathon [50, 51], MAQC/
SEQC [52–54], and GA4GH [55] consortia.
A neutral benchmark or community challenge should
be as comprehensive as possible, although for any bench-
mark there will be tradeoffs in terms of available re-
sources. To minimize perceived bias, a research group
conducting a neutral benchmark should be approximately
equally familiar with all included methods, reflectingSummary of guidelines
The guidelines in this review can be summarized
Each recommendation is discussed in more deta
1. Define the purpose and scope of the benc
2. Include all relevant methods.
3. Select (or design) representative datasets
4. Choose appropriate parameter values an
5. Evaluate methods according to key quant
6. Evaluate secondary measures including c
friendliness, installation procedures, and
7. Interpret results and provide recommenda
perspectives.
8. Publish results in an accessible format.
9. Design the benchmark to enable future ex
10. Follow reproducible research best practic
available.
Fig. 1 Summary of guidelinestypical usage of the methods by independent researchers
[3]. Alternatively, the group could include the original
method authors, so that each method is evaluated under
optimal conditions; methods whose authors decline to
take part should be reported. In either case, bias due to fo-
cusing attention on particular methods should be
avoided—for example, when tuning parameters or fixing
bugs. Strategies to avoid these types of biases, such as the
use of blinding, have been previously proposed [10].
By contrast, when introducing a new method, the focus
of the benchmark will be on evaluating the relative merits
of the new method. This may be sufficiently achieved with
a less extensive benchmark, e.g., by comparing against a
smaller set of state-of-the-art and baseline methods. How-
ever, the benchmark must still be carefully designed to
avoid disadvantaging any methods; for example, exten-
sively tuning parameters for the new method while using
default parameters for competing methods would result in
a biased representation. Some advantages of a new
method may fall outside the scope of a benchmark; for ex-
ample, a new method may enable more flexible analyses
than previous methods (e.g., beyond two-group compari-
sons in differential analyses [22]).
Finally, results should be summarized in the context of
the original purpose of the benchmark. A neutral bench-
mark or community challenge should provide clear
guidelines for method users, and highlight weaknesses in
current methods so that these can be addressed by
method developers. On the other hand, benchmarks per-
formed to introduce a new method should discuss what
the new method offers compared with the current state-
of-the-art, such as discoveries that would otherwise not
be possible.in the following set of recommendations.
il in the corresponding section in the text.
hmark.
.
d software versions.
itative performance metrics.
omputational requirements, user-
documentation quality.
tions from both user and method developer
tensions.
es, by making code and data publicly
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The selection of methods to include in the benchmark
will be guided by the purpose and scope of the study. A
neutral benchmark should include all available methods
for a certain type of analysis. In this case, the publica-
tion describing the benchmark will also function as a
review of the literature; a summary table describing the
methods is a key output (e.g., Fig. 2 in [27] or Table 1
in [31]). Alternatively, it may make sense to include
only a subset of methods, by defining inclusion criteria:
for example, all methods that (i) provide freely available
software implementations, (ii) are available for com-
monly used operating systems, and (iii) can successfully
be installed without errors following a reasonable
amount of trouble-shooting. Such criteria should be
chosen without favoring any methods, and exclusion of
any widely used methods should be justified. A useful
strategy can be to involve method authors within the
process, since they may provide additional details on
optimal usage. In addition, community involvement can
lead to new collaborations and inspire future method
development. However, the overall neutrality andTable 1 Summary of our views regarding ‘how essential’ each princ
key tradeoffs and potential pitfalls relating to each principle
Principle (see Fig. 1) How
essential?a
Tradeoffs
1. Defining the purpose and
scope
+++ How comprehensive the
benchmark should be
2. Selection of methods +++ Number of methods to include
3. Selection (or design) of
datasets
+++ Number and types of datasets t
include
4. Parameter and software
versions
++ Amount of parameter tuning
5. Evaluation criteria: key
quantitative performance
metrics
+++ Number and types of
performance metrics
6. Evaluation criteria: secondary
measures
++ Number and types of
performance metrics
7. Interpretation, guidelines,
and recommendations
++ Generality versus specificity
of recommendations
8. Publication and reporting of
results
+ Amount of resources to dedicat
to building online resources
9. Enabling future extensions ++ Amount of resources to dedicat
to ensuring extensibility
10. Reproducible research best
practices
++ Amount of resources to dedicat
to reproducibility
aThe higher the number of plus signs, the more central the principle is to the evalubalance of the resulting research team should be main-
tained. Finally, if the benchmark is organized as a com-
munity challenge, the selection of methods will be
determined by the participants. In this case, it is im-
portant to communicate the initiative widely—for
example, through an established network such as
DREAM challenges. However, some authors may
choose not to participate; a summary table document-
ing non-included methods should be provided in this
case.
When developing a new method, it is generally sufficient
to select a representative subset of existing methods to
compare against. For example, this could consist of the
current best-performing methods (if known), a simple
‘baseline’ method, and any methods that are widely used.
The selection of competing methods should ensure an ac-
curate and unbiased assessment of the relative merits of
the new approach, compared with the current state-of-
the-art. In fast-moving fields, for a truly excellent bench-
mark, method developers should be prepared to update
their benchmarks or design them to easily allow exten-
sions as new methods emerge.iple is for a truly excellent benchmark, along with examples of
Potential pitfalls
Scope too broad: too much work given available resources
Scope too narrow: unrepresentative and possibly misleading results
Excluding key methods
o Subjectivity in the choice of datasets: e.g., selecting datasets that
are unrepresentative of real-world applications
Too few datasets or simulation scenarios
Overly simplistic simulations
Extensive parameter tuning for some methods while using default
parameters for others (e.g., competing methods)
Subjectivity in the choice of metrics: e.g., selecting metrics that do
not translate to real-world performance
Metrics that give over-optimistic estimates of performance
Methods may not be directly comparable according to individual
metrics (e.g., if methods are designed for different tasks)
Subjectivity of qualitative measures such as user-friendliness, installa-
tion procedures, and documentation quality
Subjectivity in relative weighting between multiple metrics
Measures such as runtime and scalability depend on processor speed
and memory
Performance differences between top-ranked methods may be minor
Different readers may be interested in different aspects of
performance
e Online resources may not be accessible (or may no longer run)
several years later
e Selection of methods or datasets for future extensions may be
unrepresentative (e.g., due to requests from method authors)
e Some tools may not be compatible or accessible several years later
ation
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The selection of reference datasets is a critical design
choice. If suitable publicly accessible datasets cannot be
found, they will need to be generated or constructed, either
experimentally or by simulation. Including a variety of data-
sets ensures that methods can be evaluated under a wide
range of conditions. In general, reference datasets can be
grouped into two main categories: simulated (or synthetic)
and real (or experimental).
Simulated data have the advantage that a known true
signal (or ‘ground truth’) can easily be introduced; for
example, whether a gene is differentially expressed.
Quantitative performance metrics measuring the ability
to recover the known truth can then be calculated. How-
ever, it is important to demonstrate that simulations
accurately reflect relevant properties of real data, by
inspecting empirical summaries of both simulated and
real datasets (e.g., using automated tools [57]). The set
of empirical summaries to use is context-specific; for ex-
ample, for single-cell RNA-sequencing, dropout profiles
and dispersion-mean relationships should be compared
[29]; for DNA methylation, correlation patterns among
neighboring CpG sites should be investigated [58]; for
comparing mapping algorithms, error profiles of the se-
quencing platforms should be considered [59]. Simpli-
fied simulations can also be useful, to evaluate a new
method under a basic scenario, or to systematically test
aspects such as scalability and stability. However, overly
simplistic simulations should be avoided, since these will
not provide useful information on performance. A fur-
ther advantage of simulated data is that it is possible to
generate as much data as required; for example, to study
variability and draw statistically valid conclusions.
Experimental data often do not contain a ground
truth, making it difficult to calculate performance met-
rics. Instead, methods may be evaluated by comparing
them against each other (e.g., overlap between sets of
detected differential features [23]), or against a current
widely accepted method or ‘gold standard’ (e.g., manual
gating to define cell populations in high-dimensional cy-
tometry [31, 45], or fluorescence in situ hybridization to
validate absolute copy number predictions [6]). In the
context of supervised learning, the response variable to
be predicted is known in the manually labeled training
and test data. However, individual datasets should not be
overused, and using the same dataset for both method
development and evaluation should be avoided, due to
the risk of overfitting and overly optimistic results [60,
61]. In some cases, it is also possible to design experi-
mental datasets containing a ground truth. Examples in-
clude: (i) ‘spiking in’ synthetic RNA molecules at known
relative concentrations [62] in RNA-sequencing experi-
ments (e.g., [54, 63]), (ii) large-scale validation of gene
expression measurements by quantitative polymerasechain reaction (e.g., [54]), (iii) using genes located on sex
chromosomes as a proxy for silencing of DNA methyla-
tion status (e.g., [26, 64]), (iv) using fluorescence-
activated cell sorting to sort cells into known subpopula-
tions prior to single-cell RNA-sequencing (e.g., [29, 65,
66]), or (v) mixing different cell lines to create ‘pseudo-
cells’ [67]. However, it may be difficult to ensure that the
ground truth represents an appropriate level of variabil-
ity—for example, the variability of spiked-in material, or
whether method performance on cell line data is rele-
vant to outbred populations. Alternatively, experimental
datasets may be evaluated qualitatively, for example, by
judging whether each method can recover previous dis-
coveries, although this strategy relies on the validity of
previous results.
A further technique is to design ‘semi-simulated’ data-
sets that combine real experimental data with an ‘in
silico’ (i.e., computational) spike-in signal; for example,
by combining cells or genes from ‘null’ (e.g., healthy)
samples with a subset of cells or genes from samples ex-
pected to contain a true differential signal (examples in-
clude [22, 68, 69]). This strategy can create datasets with
more realistic levels of variability and correlation, to-
gether with a ground truth.
Overall, there is no perfect reference dataset, and the
selection of appropriate datasets will involve tradeoffs,
e.g., regarding the level of complexity. Both simulated
and experimental data should not be too ‘simple’ (e.g.,
two of the datasets in the FlowCAP-II challenge [45]
gave perfect performance for several algorithms) or too
‘difficult’ (e.g., for the third dataset in FlowCAP-II, no al-
gorithms performed well); in these situations, it can be
impossible to distinguish performance. In some cases,
individual datasets have also been found to be unrepre-
sentative, leading to over-optimistic or otherwise biased
assessment of methods (e.g., [70]). Overall, the key to
truly excellent benchmarking is diversity of evaluations,
i.e., using a range of metrics and datasets that span the
range of those that might be encountered in practice, so
that performance estimates can be credibly extrapolated.Parameters and software versions
Parameter settings can have a crucial impact on per-
formance. Some methods have a large number of param-
eters, and tuning parameters to optimal values can
require significant effort and expertise. For a neutral
benchmark, a range of parameter values should ideally
be considered for each method, although tradeoffs need
to be considered regarding available time and computa-
tional resources. Importantly, the selection of parameter
values should comply with the neutrality principle, i.e.,
certain methods should not be favored over others
through more extensive parameter tuning.
Weber et al. Genome Biology          (2019) 20:125 Page 5 of 12There are three major strategies for choosing parame-
ters. The first (and simplest) is to use default values for
all parameters. Default parameters may be adequate for
many methods, although this is difficult to judge in ad-
vance. While this strategy may be viewed as too simplis-
tic for some neutral benchmarks, it reflects typical
usage. We used default parameters in several neutral
benchmarks where we were interested in performance
for untrained users [27, 71, 72]. In addition, for [27], due
to the large number of methods and datasets, total run-
time was already around a week using 192 processor
cores, necessitating judgment in the scope of parameter
tuning. The second strategy is to choose parameters
based on previous experience or published values. This
relies on familiarity with the methods and the literature,
reflecting usage by expert users. The third strategy is to
use a systematic or automated parameter tuning proced-
ure—for example, a ‘grid search’ across ranges of values
for multiple parameters or techniques such as cross-
validation (e.g., [30]). The strategies may also be com-
bined, e.g., setting non-critical parameters to default
values and performing a grid search for key parameters.
Regardless, neutrality should be maintained: comparing
methods with the same strategy makes sense, while com-
paring one method with default parameters against an-
other with extensive tuning makes for an unfair
comparison.
For benchmarks performed to introduce a new
method, comparing against a single set of optimal par-
ameter values for competing methods is often sufficient;
these values may be selected during initial exploratory
work or by consulting documentation. However, as out-
lined above, bias may be introduced by tuning the pa-
rameters of the new method more extensively. The
parameter selection strategy should be transparently dis-
cussed during the interpretation of the results, to avoid
the risk of over-optimistic reporting due to expending
more ‘researcher degrees of freedom’ on the new
method [5, 73].
Software versions can also influence results, especially
if updates include major changes to methodology (e.g.,
[74]). Final results should generally be based on the lat-
est available versions, which may require re-running
some methods if updates become available during the
course of a benchmark.
Evaluation criteria: key quantitative performance metrics
Evaluation of methods will rely on one or more quanti-
tative performance metrics (Fig. 2a). The choice of
metric depends on the type of method and data. For ex-
ample, for classification tasks with a ground truth, met-
rics include the true positive rate (TPR; sensitivity or
recall), false positive rate (FPR; 1 – specificity), and false
discovery rate (FDR). For clustering tasks, commonmetrics include the F1 score, adjusted Rand index, nor-
malized mutual information, precision, and recall; some
of these can be calculated at the cluster level as well as
averaged (and optionally weighted) across clusters (e.g.,
these metrics were used to evaluate clustering methods
in our own work [28, 31] and by others [33, 45, 75]).
Several of these metrics can also be compared visually to
capture the tradeoff between sensitivity and specificity,
e.g., using receiver operating characteristic (ROC) curves
(TPR versus FPR), TPR versus FDR curves, or preci-
sion–recall (PR) curves (Fig. 2b). For imbalanced data-
sets, PR curves have been shown to be more informative
than ROC curves [76, 77]. These visual metrics can also
be summarized as a single number, such as area under
the ROC or PR curve; examples from our work include
[22, 29]. In addition to the tradeoff between sensitivity
and specificity, a method’s ‘operating point’ is important;
in particular, whether the threshold used (e.g., 5% FDR)
is calibrated to achieve the specified error rate. We often
overlay this onto TPR–FDR curves by filled or open cir-
cles (e.g., Fig. 2b, generated using the iCOBRA package
[56]); examples from our work include [22, 23, 25, 78].
For methods with continuous-valued output (e.g., ef-
fect sizes or abundance estimates), metrics include the
root mean square error, distance measures, Pearson cor-
relation, sum of absolute log-ratios, log-modulus, and
cross-entropy. As above, the choice of metric depends
on the type of method and data (e.g., [41, 79] used cor-
relation, while [48] used root mean square deviation).
Further classes of methods include those generating
graphs, phylogenetic trees, overlapping clusters, or dis-
tributions; these require more complex metrics. In some
cases, custom metrics may need to be developed (e.g.,
we defined new metrics for topologies of developmental
trajectories in [27]). When designing custom metrics, it
is important to assess their reliability across a range of
prediction values (e.g., [80, 81]). For some metrics, it
may also be useful to assess uncertainty, e.g., via confi-
dence intervals. In the context of supervised learning,
classification or prediction accuracy can be evaluated by
cross-validation, bootstrapping, or on a separate test
dataset (e.g., [13, 46]). In this case, procedures to split
data into training and test sets should be appropriate for
the data structure and the prediction task at hand (e.g.,
leaving out whole samples or chromosomes [82]).
Additional metrics that do not rely on a ground truth
include measures of stability, stochasticity, and robust-
ness. These measures may be quantified by running
methods multiple times using different inputs or sub-
sampled data (e.g., we observed substantial variability in
performance for some methods in [29, 31]). ‘Missing
values’ may occur if a method does not return any values
for a certain metric, e.g., due to a failure to converge or
other computational issues such as excessive runtime or
Evaluation criteria
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b
Fig. 2 Summary and examples of performance metrics. a Schematic overview of classes of frequently used performance metrics, including examples
(boxes outlined in gray). b Examples of popular visualizations of quantitative performance metrics for classification methods, using reference datasets
with a ground truth. ROC curves (left). TPR versus FDR curves (center); circles represent observed TPR and FDR at typical FDR thresholds of 1, 5, and 10%,
with filled circles indicating observed FDR lower than or equal to the imposed threshold. PR curves (right). Visualizations in b were generated using
iCOBRA R/Bioconductor package [56]. FDR false discovery rate, FPR false positive rate, PR precision–recall, ROC receiver operating characteristic, TPR true
positive rate
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tions such as imputation may be considered in this case
[83], although these should be transparently reported.
For non-deterministic methods (e.g., with random starts
or stochastic optimization), variability in performance
when using different random seeds or subsampled data
should be characterized. Null comparisons can be con-
structed by randomizing group labels such that datasets
do not contain any true signal, which can provide infor-
mation on error rates (e.g., [22, 25, 26]). However, these
must be designed carefully to avoid confounding by
batch or population structure, and to avoid strong
within-group batch effects that are not accounted for.
For most benchmarks, multiple metrics will be rele-
vant. Focusing on a single metric can give an incomplete
view: methods may not be directly comparable if they
are designed for different tasks, and different users maybe interested in different aspects of performance. There-
fore, a crucial design decision is whether to focus on an
overall ranking, e.g., by combining or weighting multiple
metrics. In general, it is unlikely that a single method
will perform best across all metrics, and performance
differences between top-ranked methods for individual
metrics can be small. Therefore, a good strategy is to use
rankings from multiple metrics to identify a set of con-
sistently high-performing methods, and then highlight
the different strengths of these methods. For example, in
[31], we identified methods that gave good clustering
performance, and then highlighted differences in run-
times among these. In several studies, we have presented
results in the form of a graphical summary of perform-
ance according to multiple criteria (examples include
Fig. 3 in [27] and Fig. 5 in [29] from our work; and Fig.
2 in [39] and Fig. 6 in [32] from other authors).
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also be useful, to allow readers to avoid these.
Evaluation criteria: secondary measures
In addition to the key quantitative performance met-
rics, methods should also be evaluated according to
secondary measures, including runtime, scalability,
and other computational requirements, as well as
qualitative aspects such as user-friendliness, installa-
tion procedures, code quality, and documentation
quality (Fig. 2a). From the user perspective, the final
choice of method may involve tradeoffs according to
these measures: an adequately performing method
may be preferable to a top-performing method that is
especially difficult to use.
In our experience, runtimes and scalability can vary
enormously between methods (e.g., in our work, run-
times for cytometry clustering algorithms [31] and meta-
genome analysis tools [79] ranged across multiple orders
of magnitude for the same datasets). Similarly, memory
and other computational requirements can vary widely.
Runtimes and scalability may be investigated systematic-
ally, e.g., by varying the number of cells or genes in a
single-cell RNA-sequencing dataset [28, 29]. In many
cases, there is a tradeoff between performance and com-
putational requirements. In practice, if computational
requirements for a top-performing method are prohibi-
tive, then a different method may be preferred by some
users.
User-friendliness, installation procedures, and docu-
mentation quality can also be highly variable [84, 85].
Streamlined installation procedures can be ensured by
distributing the method via standard package repositor-
ies, such as CRAN and Bioconductor for R, or PyPI for
Python. Alternative options include GitHub and other
code repositories or institutional websites; however,
these options do not provide users with the same guar-
antees regarding reliability and documentation quality.
Availability across multiple operating systems and within
popular programming languages for data analysis is also
important. Availability of graphical user interfaces can
further extend accessibility, although graphical-only
methods hinder reproducibility and are thus difficult to
include in a systematic benchmark.
For many users, freely available and open source soft-
ware will be preferred, since it is more broadly accessible
and can be adapted by experienced users. From the
developer perspective, code quality and use of software
development best practices, such as unit testing and
continuous integration, are also important. Similarly, ad-
herence to commonly used data formats (e.g., GFF/GTF
files for genomic features, BAM/SAM files for sequence
alignment data, or FCS files for flow or mass cytometry
data) greatly improves accessibility and extensibility.High-quality documentation is critical, including help
pages and tutorials. Ideally, all code examples in the
documentation should be continually tested, e.g., as Bio-
conductor does, or through continuous integration.
Interpretation, guidelines, and recommendations
For a truly excellent benchmark, results must be clearly
interpreted from the perspective of the intended audi-
ence. For method users, results should be summarized
in the form of recommendations. An overall ranking of
methods (or separate rankings for multiple evaluation
criteria) can provide a useful overview. However, as
mentioned above, some methods may not be directly
comparable (e.g. since they are designed for different
tasks), and different users may be interested in different
aspects of performance. In addition, it is unlikely that
there will be a clear ‘winner’ across all criteria, and per-
formance differences between top-ranked methods can
be small. Therefore, an informative strategy is to use the
rankings to identify a set of high-performing methods,
and to highlight the different strengths and tradeoffs
among these methods. The interpretation may also in-
volve biological or other domain knowledge to establish
the scientific relevance of differences in performance.
Importantly, neutrality principles should be preserved
during the interpretation.
For method developers, the conclusions may include
guidelines for possible future development of methods.
By assisting method developers to focus their research
efforts, high-quality benchmarks can have significant im-
pact on the progress of methodological research.
Limitations of the benchmark should be transparently
discussed. For example, in [27] we used default parame-
ters for all methods, while in [31] our datasets relied on
manually gated reference cell populations as the ground
truth. Without a thorough discussion of limitations, a
benchmark runs the risk of misleading readers; in ex-
treme cases, this may even harm the broader research
field by guiding research efforts in the wrong directions.
Publication and reporting of results
The publication and reporting strategy should emphasize
clarity and accessibility. Visualizations summarizing
multiple performance metrics can be highly informative
for method users (examples include Fig. 3 in [27] and
Fig. 5 in [29] from our own work; as well as Fig. 6 in
[32]). Summary tables are also useful as a reference (e.g.,
[31, 45]). Additional visualizations, such as flow charts
to guide the choice of method for different analyses, are
a helpful way to engage the reader (e.g., Fig. 5 in [27]).
For extensive benchmarks, online resources enable
readers to interactively explore the results (examples
from our work include [27, 29], which allow users to fil-
ter metrics and datasets). Figure 3 displays an example
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Fig. 3 Example of an interactive website allowing users to explore the results of one of our benchmarking studies [27]. This website was created
using the Shiny framework in R
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[27], which facilitates exploration of results and assists
users with choosing a suitable method. While tradeoffs
should be considered in terms of the amount of work re-
quired, these efforts are likely to have significant benefit
for the community.
In most cases, results will be published in a peer-
reviewed article. For a neutral benchmark, the bench-
mark will be the main focus of the paper. For a bench-
mark to introduce a new method, the results will form
one part of the exposition. We highly recommend pub-
lishing a preprint prior to peer review (e.g., on bioRxiv
or arXiv) to speed up distribution of results, broaden ac-
cessibility, and solicit additional feedback. In particular,
direct consultation with method authors can generate
highly useful feedback (examples from our work are de-
scribed in the acknowledgments in [79, 86]). Finally, at
publication time, considering open access options will
further broaden accessibility.
Enabling future extensions
Since new methods are continually emerging [1], bench-
marks can quickly become out of date. To avoid this, a
truly excellent benchmark should be extensible. For ex-
ample, creating public repositories containing code and
data allows other researchers to build on the results to in-
clude new methods or datasets, or to try different param-
eter settings or pre-processing procedures (examples from
our work include [27–31]). In addition to raw data and
code, it is useful to distribute pre-processed and/or results
data (examples include [28, 29, 56] from our work and
[75, 87, 88] from others), especially for computationally
intensive benchmarks. This may be combined with an
interactive website, where users can upload results from a
new method, to be included in an updated comparisoneither automatically or by the original authors (e.g., [35,
89, 90]). ‘Continuous’ benchmarks, which are continually
updated, are especially convenient (e.g., [91]), but may re-
quire significant additional effort.
Reproducible research best practices
Reproducibility of research findings has become an in-
creasing concern in numerous areas of study [92]. In
computational sciences, reproducibility of code and data
analyses has been recognized as a useful ‘minimum
standard’ that enables other researchers to verify ana-
lyses [93]. Access to code and data has previously
enabled method developers to uncover potential errors
in published benchmarks due to suboptimal usage of
methods [74, 94, 95]. Journal publication policies can
play a crucial role in encouraging authors to follow these
practices [96]; experience shows that statements that
code and data are ‘available on request’ are often insuffi-
cient [97]. In the context of benchmarking, code and
data availability also provides further benefits: for
method users, code repositories serve as a source of
annotated code to run methods and build analysis pipe-
lines, while for developers, code repositories can act as a
prototype for future method development work.
Parameter values (including random seeds) and soft-
ware versions should be clearly reported to ensure
complete reproducibility. For methods that are run using
scripts, these will be recorded within the scripts. In R,
the command ‘sessionInfo()’ gives a complete summary
of package versions, the version of R, and the operating
system. For methods only available via graphical inter-
faces, parameters and versions must be recorded manu-
ally. Reproducible workflow frameworks, such as the
Galaxy platform [98], can also be helpful. A summary
table or spreadsheet of parameter values and software
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along with the publication describing the benchmark
(e.g., Supporting Information Table S1 in our study
[31]).
Automated workflow management tools and special-
ized tools for organizing benchmarks provide sophisti-
cated options for setting up benchmarks and creating a
reproducible record, including software environments,
package versions, and parameter values. Examples in-
clude SummarizedBenchmark [99], DataPackageR [100],
workflowr [101], and Dynamic Statistical Comparisons
[102]. Some tools (e.g., workflowr) also provide stream-
lined options for publishing results online. In machine
learning, OpenML provides a platform to organize and
share benchmarks [103]. More general tools for man-
aging computational workflows, including Snakemake
[104], Make, Bioconda [105], and conda, can be custom-
ized to capture setup information. Containerization tools
such as Docker and Singularity may be used to encapsu-
late a software environment for each method, preserving
the package version as well as dependency packages and
the operating system, and facilitating distribution of
methods to end users (e.g., in our study [27]). Best prac-
tices from software development are also useful, includ-
ing unit testing and continuous integration.
Many free online resources are available for sharing
code and data, including GitHub and Bitbucket, reposi-
tories for specific data types (e.g., ArrayExpress [106],
the Gene Expression Omnibus [107], and FlowReposi-
tory [108]), and more general data repositories (e.g., fig-
share, Dryad, Zenodo, Bioconductor ExperimentHub,
and Mendeley Data). Customized resources (examples
from our work include [29, 56]) can be designed when
additional flexibility is needed. Several repositories allow
the creation of ‘digital object identifiers’ (DOIs) for code
or data objects. In general, preference should be given to
publicly funded repositories, which provide greater guar-
antees for long-term archival stability [84, 85].
An extensive literature exists on best practices for re-
producible computational research (e.g., [109]). Some
practices (e.g., containerization) may involve significant
additional work; however, in our experience, almost all
efforts in this area prove useful, especially by facilitating
later extensions by ourselves or other researchers.
Discussion
In this review, we have described a set of key principles
for designing a high-quality computational benchmark.
In our view, elements of all of these principles are essen-
tial. However, we have also emphasized that any bench-
mark will involve tradeoffs, due to limited expertise and
resources, and that some principles are less central to
the evaluation. Table 1 provides a summary of examples
of key tradeoffs and pitfalls related to benchmarking,along with our judgment of how truly ‘essential’ each
principle is.
A number of potential pitfalls may arise from bench-
marking studies (Table 1). For example, subjectivity in
the choice of datasets or evaluation metrics could bias
the results. In particular, a benchmark that relies on un-
representative data or metrics that do not translate to
real-world scenarios may be misleading by showing poor
performance for methods that otherwise perform well.
This could harm method users, who may select an in-
appropriate method for their analyses, as well as method
developers, who may be discouraged from pursuing
promising methodological approaches. In extreme cases,
this could negatively affect the research field by influen-
cing the direction of research efforts. A thorough discus-
sion of the limitations of a benchmark can help avoid
these issues. Over the longer term, critical evaluations of
published benchmarks, so-called meta-benchmarks, will
also be informative [10, 13, 14].
Well-designed benchmarking studies provide highly
valuable information for users and developers of compu-
tational methods, but require careful consideration of a
number of important design principles. In this review,
we have discussed a series of guidelines for rigorous
benchmarking design and implementation, based on our
experiences in computational biology. We hope these
guidelines will assist computational researchers to design
high-quality, informative benchmarks, which will con-
tribute to scientific advances through informed selection
of methods by users and targeting of research efforts by
developers.
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